Literature DB >> 30311471

Torch Ginger (<I>Etlingera elatior</I>): A Review on its Botanical Aspects, Phytoconstituents and Pharmacological Activities.

Tanti Juwita, Irma Melyani Puspitasari, Jutti Levita.   

Abstract

In order to propose a prospective candidate for novel complementary phytopharmaceuticals, one of Zingiberaceae family plant, Etlingeraelatior or torch ginger, was being evaluated. The aim of this review was to provide a comprehensive literature research focused on the botanical aspects, nutritional quality, phytoconstituents and pharmacological activities of E. elatior. Researches on this particular plant were conducted in Malaysia (55.5%), Indonesia (33.3%), Thailand (8.3%) and Singapore (2.7%). This review article has revealed that the most prominent pharmacological activities were anti-microbial, anti-oxidant and anti-tumor activities in consistent with the dominated levels of flavonoids, terpenoids and phenols. However, extended and integrated research should be converged towards intensive investigations concerning to isolated phytoconstituents and its bioactivities, pharmacokinetics, bioavailability, molecular mechanism of its specific pharmacological activities, safety and efficacy studies for further development.

Entities:  

Keywords:  Etlingeraelatior; flavonoids; kaempferol; quercetin; zingiberaceae

Mesh:

Substances:

Year:  2018        PMID: 30311471     DOI: 10.3923/pjbs.2018.151.165

Source DB:  PubMed          Journal:  Pak J Biol Sci        ISSN: 1028-8880


  2 in total

1.  Chemical analysis and anticancer activity of sesterterpenoid from an endophytic fungus Hypomontagnella monticulosa Zg15SU and its host Zingiber griffithii Baker.

Authors:  Anisa Lutfia; Erman Munir; Yurnaliza Yurnaliza; Mohammad Basyuni
Journal:  Heliyon       Date:  2021-02-16

2.  Etlingera elatior Flower Aqueous Extract Protects against Oxidative Stress-Induced Nephropathy in a Rat Model of Type 2 Diabetes.

Authors:  Liza Noordin; Wan Amir Nizam Wan Ahmad; Nor Asiah Muhamad Nor; Nor Hidayah Abu Bakar; Azizah Ugusman
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-23       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.